Researchers unravel mechanisms that produce individualized m

Researchers unravel mechanisms that produce individualized metabolism in leukemia


Researchers unravel mechanisms that produce individualized metabolism in leukemia
A research collaboration based in Kumamoto University (Japan) has shown that lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells are known to have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. The new research findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types.
Acute myelogenous leukemia (AML) occurs when hematopoietic stem cells become tumors rather than differentiating into white or red blood cells. The various types of AML develop according to which stage of differentiation they become cancerous. Those that develop when differentiating into red blood cells are classified as erythroblastic leukemia (EL). Although pathology-specific targeted molecular therapies have been developed for some forms of AML, and have improved treatment outcomes, many forms of the disease, including EL, have high mortality rates due to the lack of individualized therapies. Thus, therapies based on disease type and molecular pathology are desired.

Related Keywords

Shinjiro Hino , Emily Henderson , Cancer Research , Kumamoto University , Nature Communications , Kumamoto University Japan , Nucleic Acids Research , Associate Professor Shinjiro Hino , எமிலி ஹென்டர்சன் , புற்றுநோய் ஆராய்ச்சி , குமாமோடோ பல்கலைக்கழகம் , இயற்கை தகவல்தொடர்புகள் , குமாமோடோ பல்கலைக்கழகம் ஜப்பான் ,

© 2025 Vimarsana